Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 5;8(3):6257.
doi: 10.4081/rt.2016.6257. eCollection 2016 Sep 5.

National Incidence, Management and Survival of Urachal Carcinoma

Dearbhaile C Collins  1 , Kyra Velázquez-Kennedy  1 , Sandra Deady  2 , Adrian P Brady  3 , Paul Sweeney  4 , Derek G Power  1
Affiliations

National Incidence, Management and Survival of Urachal Carcinoma

Dearbhaile C Collins et al. Rare Tumors. .

Abstract

Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were identified from the National Cancer Registry in Ireland. Data obtained included patient age, gender, diagnostic year, pathology, tumor stage, patient treatment strategies and survival. Twenty-six urachal carcinomas were identified, the majority being adenocarcinoma. This comprised 0.3% of all invasive bladder tumors. Patients were predominantly male (62%) and over 50 years of age (58%). Twenty-two patients (85%) underwent surgery, with only six (23%) undergoing chemotherapy. On average, median overall survival was 2.6 years (range 0-15.2 yrs). Survival was longer in women (5 vs. 1.9 yrs), patients under 50 years of age (3.6 vs. 1.9 yrs), those without confirmed metastasis (4.1 vs. 0.7 yrs) and those who received chemotherapy (3.6 vs. 2.6 yrs). The overall survival of urachal carcinoma in Ireland is less than expected from published literature. This study highlights the need for centralization of rare tumors with international collaboration to identify the optimal treatment strategy and improve outcome.

Keywords: Urachal carcinoma; epidemiology; management; survival.

PubMed Disclaimer

Conflict of interest statement

the authors declare no potential conflict of interest.

Figures

Figure 1.
Figure 1.
Annual incidence of urachal cancer (values on left) and invasive bladder cancer (values on right) diagnosed from 1994-2011.
See this image and copyright information in PMC

References

    1. NCCN. Guidelines in Oncology (NCCN Guidelines). Bladder Cancer 2013. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
    1. Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol 1984;131:1-8. - PubMed
    1. Hayashi T, Yuasa T, Uehara S, et al. Clinical outcome of urachal cancer in Japanese patients. Int J Clin Oncol 2016;21:133-8. - PubMed
    1. Hue L, Jacquin M. Cancer colloide de la lombille et de paroi abdominale anterieure ayant envahi la vessie. Union Med de la Siene-Inf Rouen 1863;6:418-20.
    1. Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. J Urol 2003;169:1295-8. - PubMed

LinkOut - more resources